Phathom Pharmaceuticals, Inc. PHAT Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- Phathom Pharmaceuticals, Inc. (PHAT) reported accrued progress collections and price adjustments of $347.9M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments increased by 1.2% year-over-year, from $343.81M to $347.9M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- Over 3 years (2022 to 2025), Phathom Pharmaceuticals, Inc.'s accrued progress collections and price adjustments has grown at a 47.3% compound annual growth rate (CAGR), from $109.53M to $350.12M.